Repurposing Infectious Disease Hits as Anti-Cryptosporidium Leads.

Abstract

New drugs are critically needed to treat Cryptosporidium infections, particularly for malnourished children under 2 years old in the developing world and persons with immunodeficiencies. Bioactive compounds from the Tres-Cantos GSK library that have activity against other pathogens were screened for possible repurposing against Cryptosporidium parvum growth. Nineteen compounds grouped into nine structural clusters were identified using an iterative process to remove excessively toxic compounds and screen related compounds from the Tres-Cantos GSK library. Representatives of four different clusters were advanced to a mouse model of C. parvum infection, but only one compound, an imidazole-pyrimidine, led to significant clearance of infection. This imidazole-pyrimidine compound had a number of favorable safety and pharmacokinetic properties and was maximally active in the mouse model down to 30 mg/kg given daily. Though the mechanism of action against C. parvum was not definitively established, this imidazole-pyrimidine compound inhibits the known C. parvum drug target, calcium-dependent protein kinase 1, with a 50% inhibitory concentration of 2 nM. This compound, and related imidazole-pyrimidine molecules, should be further examined as potential leads for Cryptosporidium therapeutics.

• Authors: Matthew A Hulverson, Ryan Choi, Molly C McCloskey, Grant R Whitman, Kayode K Ojo, Samantha A Michaels, Mastanbabu Somepalli, Melissa S Love, Case W McNamara, Lesley M Rabago, Lynn K Barrett, Christophe L M J Verlinde, Samuel L M Arnold, Boris Striepen, Dolores Jimenez-Alfaro, Lluis Ballell, Elena Fernández, M Nicole Greenwood, Laura de Las Heras, Felix Calderón, Wesley C Van Voorhis
• Journal: ACS infectious diseases (ACS Infect Dis) Vol. 7 Issue 5 Pg. 1275-1282 (05 14 2021) ISSN: 2373-8227 [Electronic] United States
• PMID: 33740373 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Topics

• Communicable Diseases
• Cryptosporidiosis (drug therapy)
• Cryptosporidium
• Cryptosporidium parvum
• Drug Repositioning
• Humans
• Infant